Molbio Diagnostics Targets ₹940 Crore with Ambitious IPO Plan

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) to raise ₹940 crore. The company plans to use ₹200 crore of this to bolster its capital expenditures, while an additional ₹740 crore will be generated through an offer for sale, reducing the promoter group's stake from 46.6% to 43%.

Global Reach and Revenue Growth

Headquartered in India, Molbio Diagnostics operates six manufacturing sites and serves customers in over 90 countries. Its growth is largely driven by its tuberculosis diagnostic test kits, which contribute significantly to its revenue. In fact, the company reported a 31.5% annual increase in revenue, reaching ₹1,445.7 crore between FY24 and FY26, while net profits surged by 40.2% to ₹164.1 crore during the same period.

The company’s flagship product, the 'Truenat' platform, is a portable diagnostics system designed for resource-limited settings and offers rapid test results. This platform is pivotal in providing molecular testing solutions for over 30 diseases through 43 diagnostic assays.

Investment Appeal and Financial Metrics

Molbio's financial performance has been robust, with an operating profit before interest, tax, depreciation, and amortisation (Ebitda) rising by 33.2% to ₹328.2 crore. The Ebitda margin has also improved to 22.6% in FY26 from 22% in FY24. On a year-on-year basis, FY26 saw a 41.7% increase in revenue, a 27.9% rise in Ebitda, and an 18.4% growth in net profit.

The IPO's valuation demands a price-earnings (P/E) multiple of up to 57. While Molbio has no direct listed peers in India, its valuation stands in comparison to other healthcare diagnostics and medical device companies like Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples ranging from 54 to 81.

Market Dynamics and Future Prospects

Incorporated in 2000, Molbio Diagnostics has carved out a niche in both infectious and non-communicable disease diagnostics. The company’s clientele includes government and international aid agencies, which account for over 80% of its revenue, indicating a high level of customer concentration.

Investors with a high-risk appetite might find the IPO attractive given Molbio's strong revenue growth and strategic positioning in the diagnostics market. However, the reliance on a few key clients could pose risks if market dynamics shift.